Worklife Expectancy Research Articles

Trends in Working Life Expectancy in Europe.

The aim of the article is to analyze past and present developments of working life expectancy (WLE) at age 50 by age, sex, and education in Europe. WLE is also compared with life expectancy (LE) and healthy life expectancy (HLE). WLE is calculated with the Sullivan method. Labor force participation is based on the European Union (EU) Labor Force Survey. WLE at age 50 has been increasing since the mid- to late 1990s in most European countries. Increases were more pronounced among women than men. Differences in WLE by education are substantial. The comparison of WLE, LE, and HLE for the year 2009 reveals that the correlation between WLE and LE is smaller than between WLE and HLE. The analysis of trends in WLE at age 50, particularly when set in relation to remaining LE, provides useful insights about the development of the distribution of economically active and inactive years in Europe's aging societies.

Becoming a blind teacher in Turkey: A long journey.

The story of Hakan profoundly calls attention to the dialectical relationship between the macro and the micro influences on the social and political situated nature of disability, work life expectations and the transformative power of life-long learning. All of these are reflected in Hakan's journey and his capacity to self-manage his needs and adapt in spite of disability adversity and impairment challenges at the turning points in his life. He used his ingenuity when faced with challenges by tapping into non-disabling environments (finding a university program that fit with his needs and he was able to meet standard examination expectations) and familiar human relationships (finding friends or family that agreed to read to him). His early experiences in the formal and informal labour markets that were available to him provided grounding into various workplace acumen and social requirements. In effect these experiences were part of his early employment socialization that are often overlooked as essential to being ready to shift from a job to deciding on a career in a changing labour economy. While Hakan developed his capacity and competencies to be ready for work in a viable career, the policy's of prescriptive employment for the disabled shifted slightly to open up the door to more persons with impairments. Read on to find out the details of Hakan's numerous experiences with turning points, shifts and his efforts to persist in becoming a teacher. Following this article there are reflective questions for deeper consideration and contemplation of the many relationships that shaped the journey.

Tracking safety performance in construction: A focused approach to the measurement of fatal and non-fatal injuries, 2003–2012

This analysis develops a Basic Model focusing on the loss of productive time resulting from death or injury as of prime importance in measuring trends in the safety environment supplemented by a Financial Model measuring loss in dollar terms. This provides two views of the impact of death and injury in the construction industry in the 41 states for which comparable fatality and injury data were available for the period 2003 through 2012. This period is significant in that it includes periods of boom, bust and recovery. In undertaking this study we developed a state-by-state measure of lost work-life expectancy due to fatalities.Traditional approaches to costing have tended to focus on medical costs, workers’ compensation employment cost and other cost elements as well as victim productivity. In this analysis the impact of death and injury on the individuals involved is the focus with other factors treated as secondary.Applying the Basic and Financial Models to the 2003–2012 period results in findings showing notable improvement in construction safety.

In Process Citation

Approximately 70.000 people are infected with hepatitis C virus in Hungary, more than half of whom are not aware of their infection. From the point of infected individuals early recognition and effective treatment of related liver injury may prevent consequent advanced liver diseases and complications (liver cirrhosis, liver failure and liver cancer) and can increase work productivity and life expectancy on one hand. From socioeconomic aspect, this could also prevent further spread of the virus as well as reduce substantially long term financial burden of related morbidity. Available since 2003 in Hungary, pegylated interferon + ribavirin dual therapy can clear the virus in 40-45% of previously not treated (naïve), and in 5-21% of previous treatment-failure patients. Addition of a direct acting first generation protease inhibitor drug (boceprevir or telaprevir) to the dual therapy increases the chance of sustained virologic response to 63-75% and 59-66%, respectively. These two protease inhibitors are available and financed for a segment of Hungarian patients since May 2013. Between 2013 and February 2015, other direct acting antiviral interferon-free combination therapies have been registered for the treatment of chronic hepatitis C, with a potential efficacy over 90% and typical short duration of 8-12 weeks. Indication of therapy includes exclusion of contraindications to the drugs and demonstration of viral replication with consequent liver injury, i.e., inflammation and or fibrosis in the liver. Non-invasive methods (eleastography and biochemical methods) are accepted and preferred for staging liver damage (fibrosis). For initiation of treatment accurate and timely molecular biology tests are mandatory. Eligibility for treatment is a subject of individual central medical review. Due to budget limitations tharpy is covered only for a proportion of patients by the National Health Insurance Fund. Priority is given to those with urgent need based on a Hungarian Priority Index system reflecting primarily the stage of liver disease, and considering also additional factors, i.e., activity and progression of liver disease, predictive factors of treatment and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained virologic response value in different patient categories with consensus between professional organizations, National Health Insurance Fund and patient organizations. More expensive therapies might be available upon co-financing by the patient or a third party. Interferon-free treatments and shorter therapy durations preferred as much as financially feasible. A separate budget is allocated to cover interferon-free treatments for the most-in-need interferon ineligible/intolerant patients, and for those who have no more interferon-based therapy option. Orv. Hetil., 2015, 156(Suppl. 2), 3-24.

Transitions Into and Out of Census Disability

Abstract This paper examines disability as measured and reported in three Census surveys: the American Community Survey (ACS), the Current Population Survey (CPS), and the Survey on Income Program Participation (SIPP). We focus on whether person-specific disability, as measured by the Census, is a permanent or a transitory condition. Survey data results regarding the incidence of Census-measured disability are shown both cross-sectionally and longitudinally. It is found from longitudinal CPS and SIPP responses that Census-measured disability is largely transitory. That finding empirically confirms the longstanding theoretical objections to the use of Census cross-section disability data along with a permanent disability assumption in worklife expectancy models; hence, any worklife expectancy model which assumes that Census disability measures are permanent conditions is misspecified and empirically invalid. Instead of using the permanent disability assumption, we use actual longitudinal disability transition probabilities and life table analysis to quantify the lifetime duration of disability as measured by the Census in total life years and working life years. We show that the realistic feature of disability transition dramatically lowers the effect of disability on worklife expectancy.

Working Life and Retirement Expectancies at Age 50 by Social Class: Period and Cohort Trends and Projections for Finland.

The balance between the amount of time spent in work and in retirement underlies the long-term sustainability of the social security system. We examined socioeconomic differences in how increasing longevity is distributed between labor market statuses in Finland. We used register data and the Sullivan method to analyze life expectancy at age 50 spent in different labor market statuses over the period 1989-2012 and across cohorts born in 1938-1953. We projected the future mortality and labor market participation rates of partially observed cohorts. Both working life expectancy at age 50 and the share of remaining life spent in work have increased across periods following the recession of the early 1990s, and across successive cohorts. The trends were similar across the social classes, but there were large differences in the numbers of years spent in various states: for the most recent period and the youngest cohort, we find that compared with upper non-manual employees, male and female manual workers were expected to spend 3.6-3.7 fewer years in work, 1.7-4.7 fewer years in statutory retirement, and 3.2-3.9 more years in other forms of nonemployment. Our finding that the share of remaining life at age 50 spent in work is increasing implies that pressure on the welfare system is not as severe as is commonly thought.

Living, working and earning for people with disabilities in Australia

The purpose of this article is to consider the extent to which disabilities are likely to affect the length of a career and earnings potential. The net worklife expectancy for persons with a profound, severe, moderate or mild disability in Australia was determined. This was compared this to those with no disability. Tables for five-year age groups to age 65 are produced for males and females. There is a marked theoretical reduction of worklife capacity at all levels of disability and across every age group. The net effect of restricted vocational potential is likely to be a reduced worklife and diminished earnings for those with disabilities. This finding is considered in the light of current career development theory and practice.

Is Race- and Sex-Based Targeting Efficient? A Closer Look at Tort Law's Discriminatory Damage Awards

Inherent within current tort law are incentives to target individuals and communities based on race and gender. Surprisingly, the basis for this targeting is the seemingly neutral use of three different race- and gender-based statistical tables (for wages, life expectancy and worklife expectancy) which, when used in tort damage calculations, result in a large disparity between damages awarded to whites versus blacks, and men versus women. Thus, tort law’s remedial damage scheme perpetuates existing racial and gender inequalities by compensating individuals, especially children, based on their race and gender. Even worse, tort law creates ex-ante incentives for potential tortfeasors to engage in future discriminatory targeting of women and minorities. This paper provides the first full account of courts' existing discriminatory practices. The paper then addresses the deficiencies in the non-blended tables that courts use (tables that use race and gender as discriminating factors) and the reasons behind their continued use. The paper shows how the various theories of tort law (corrective justice, distributive justice, and economic efficiency) have contributed to a misunderstanding of the proper damages calculation, and illustrates how the very same theories can be used to engender a change in the current praxis. It then challenges the conventional wisdom that the use of race- and gender-based tables is justified on efficiency grounds, pointing out fatal flaws inherent in the tables, in how they are used in courts to calculate damages for individuals, and in the incentives they create. The paper then reveals that similar discriminatory practices ironically exist in federal law such as the Americans with Disabilities Act and even Title VII whose main goal is to combat gender and race discrimination. Finally, this paper proposes a feasible, low cost, and logical solution that pushes toward a more efficient and less discriminatory tort law remedial system: courts should immediately stop using non-blended tables.

Part-Time Event Management Employee Expected Quality of Work Life

Research has highlighted the importance of quality of work life in hotels and restaurants, with less attention paid to event management. Given the rapid growth of event management in Hong Kong and consequent increase in demand for part-time staff, this study investigated the quality of work life expectations and perceptions among such staff. Data from in-depth interviews with 10 event management practitioners were analysed using grounded theory. The results suggest that event management organisations can develop human resource policies to improve both the quality of their part-time employees’ work lives and the fit between staff members’ needs and organisational benefits.

Does living longer in good health facilitate longer working lives? The relationship between disability and working lives.

Improvements in life expectancy have fuelled debates about the statutory retirement age in many European countries. This article contributes to this debate by investigating how changes in disability may influence both employment outcomes and disability-free life expectancy. We used data from the European Community Household Panel to estimate the impact of disability incidence on labour supply by country using propensity score techniques. In a second step, we translated the estimated effects of disability incidence into effects on working life expectancy as well as disability-free life expectancy using multi-state life tables. Results from the matching analysis show that individuals who become disabled are more likely to leave the labour market. However, the size of the effect is much weaker than a simple descriptive analysis suggests and varies by country. A 10% decrease in disability incidence results in increases in disability-free life expectancy and working life expectancy of respectively 0.6 and 0.07 years on average. A large part of the differences in employment between disabled and non-disabled individuals is not due to a causal effect of disability on employment. Policies that reduce disability incidence increase disability-free life expectancy but have only a limited impact on working life expectancy.

Directed search over the life cycle

We develop a life-cycle model of the labor market in which different worker–firm matches have different quality and the assignment of the right workers to the right firms is time consuming because of search and learning frictions. The rate at which workers move between unemployment, employment and across different firms is endogenous because search is directed and, hence, workers can choose whether to seek low-wage jobs that are easy to find or high-wage jobs that are hard to find. We calibrate our theory using data on labor market transitions aggregated across workers of different ages. We validate our theory by showing that it predicts quite well the pattern of labor market transitions for workers of different ages. Finally, we use our theory to decompose the age profiles of transition rates, wages and productivity into the effects of age variation in work-life expectancy, human capital and match quality.

Diagnosis, treatment, and follow-up of hepatitis C virus related liver disease.Hungarian national consensus guideline

Approximately 70,000 people are infected with hepatitis C virus in Hungary, and more than half of them are not aware of their infection. From the point of infected individuals early recognition and effective treatment of related liver injury may prevent consequent advanced liver diseases and complications (liver cirrhosis, liver failure and liver cancer) and can increase work productivity and life expectancy. From a socioeconomic aspect, this could also prevent further spread of the virus as well as reduce substantially long term financial burden of related morbidity. Pegylated interferon + ribavirin dual therapy, which is available in Hungary since 2003, can clear the virus in 40-45% of previously not treated (naïve), and in 5-21% of previous treatment-failure patients. Addition of a direct acting first generation protease inhibitor drug (boceprevir or telaprevir) to the dual therapy increases the chance of sustained viral response to 63-75% and 59-66%, respectively. These two protease inhibitors are available and financed for a segment of Hungarian patients since May 2013. Between 2013 and February 2015, other direct acting antiviral interferon-free combination therapies have been registered for the treatment of chronic hepatitis C, with a potential efficacy over 90% and typical short duration of 8-12 weeks. Indication of therapy includes exclusion of contraindications to the drugs and demonstration of viral replication with consequent liver injury, i.e., inflammation and / or fibrosis in the liver. Non-invasive methods (elastography and biochemical methods) are accepted and preferred for staging liver damage (fibrosis). For initiation of treatment as well as for on-treatment decisions, accurate and timely molecular biology tests are mandatory. Eligibility for treatment is a subject of individual central medical review. Due to budget limitations therapy is covered only for a proportion of patients by the National Health Insurance Fund. Priority is given to those with urgent need based on a Hungarian Priority Index system reflecting primarily the stage of liver disease, and considering also additional factors, i.e., activity and progression of liver disease, predictive factors of treatment and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained viral response value in different patient categories with consensus between professional organizations, National Health Insurance Fund and patient organizations. More expensive therapies might be available upon co-financing by the patient or a third party. Interferon-free treatments and shorter therapy durations preferred as much as financially feasible. A separate budget is allocated to cover interferon-free treatments for the most-in-need interferon ineligible/intolerant patients, and for those who have no more interferon-based therapy option. Orv. Hetil., 2015, 156(Suppl. 1), 3-23.

Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline

Approximately 70,000 people are infected with hepatitis C virus in Hungary, and more than half of them are not aware of their infection. From the point of infected individuals early recognition and effective treatment of related liver injury may prevent consequent advanced liver diseases and complications (liver cirrhosis, liver failure and liver cancer) and can increase work productivity and life expectancy. Furthermore, these could from prevent further spread of the virus as well as reduce substantially long term financial burden of related morbidity, as a socioeconomic aspect. Pegylated interferon + ribavirin dual therapy, which is available in Hungary since 2003, can clear the virus in 40-45% of previously not treated (naïve), and in 5-21% of previous treatment-failure patients. Addition of a direct acting first generation protease inhibitor drug (boceprevir or telaprevir) to the dual therapy increases the chance of sustained viral response to 63-75% and 59-66%, respectively. These two protease inhibitors are available and financed for a segment of Hungarian patients since May 2013. Between 2013 and February 2015, other direct acting antivirals and interferon-free combination therapies have been registered for the treatment of chronic hepatitis C with a potential efficacy over 90% and typically with a short duration of 8-12 weeks. Indication of therapy includes exclusion of contraindications to the drugs and demonstration of viral replication with consequent liver injury, i.e., inflammation and/or fibrosis in the liver. Non-invasive methods (elastography and biochemical methods) are accepted and preferred for staging liver damage (fibrosis). For initiation of treatment accurate and timely molecular biology tests are mandatory. Eligibility for treatment is a subject of individual central medical review. Due to budget limitations therapy is covered only for a proportion of patients by the National Health Insurance Fund. Priority is given to those with urgent need based on a Hungarian Priority Index system reflecting primarily the stage of liver disease, and considering also additional factors, i.e., activity and progression of liver disease, predictive factors of treatment and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained viral response value in different patient categories with consensus between professional organizations, National Health Insurance Fund and patient organizations. More expensive therapies might be available upon co-financing by the patient or a third party. Interferon-free treatments and shorter therapy durations preferred as much as financially feasible. A separate budget is allocated to cover interferon-free treatments for the most-in-need interferon ineligible/intolerant patients, and for those who have no more interferon-based therapy option.

Human Capital Choice and the Wage Gap: The Role of Worklife Expectancy and Statistical Discrimination

This paper explores the link between worklife expectancy, educational attainment and its impact on the wage gap. A model of statistical discrimination that accounts for the achievement gap and differences in worklife expectancy demonstrates that (a) the achievement gap does not influence educational attainment directly through the choice of human capital, (b) discrimination lowers human capital directly through lower wage offers, and (c) lower worklife expectancy leads to lower human capital accumulation. While sufficient data on worklife expectancy by race and education is not available for a detailed empirical analysis, a simple calibration suggests the importance of the achievement gap and worklife expectancy relative to traditional labor market discrimination.

Worklife Expectancy of Railroad Workers Based on the Twenty-Fifth Actuarial Valuation Using Both Competing Risks/Multiple Decrement Theory and the Markov Railroad Model

Abstract The U. S. Railroad Retirement Board's Bureau of the Actuary publishes valuations of the retirement plan for railroad workers every three years. The most current report, the Twenty-Fifth Actuarial Valuation, released in August 2012 covers the years 2008-10. We use data on mortality, disability retirements, age retirements, and other final withdrawals contained in the Technical Supplement of this valuation to estimate worklife expectancies (WLE) of railroad workers. There are substantial changes in WLE when compared to WLE based on the Twenty-Third Actuarial Valuation and the Twenty-Fourth Valuation. We identify the sources of these changes. In addition to WLE, we estimate entire probability mass functions and provide summary measures of distributional characteristics of time spent in railroad work. Our main results use a competing risks/multiple decrement model, but we also provide WLE based on the railroad Markov process model and show that the former model is also a Markov model, albeit a different Markov model from the railroad Markov model.

Healthy Working Life Expectancies of Mid-Aged and Older Koreans

Healthy Working Life Expectancies of Mid-Aged and Older Koreans

Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe.

Every cancer-related death in someone of working age represents an economic loss to society. To inform priorities for cancer control, we estimated costs of lost productivity due to premature cancer-related mortality across Europe, for all cancers and by site, gender, region and country. Cancer deaths in 2008 were obtained from GLOBOCAN for 30 European countries across four regions. Costs were valued using the human capital approach. Years of productive life lost (YPLL) were computed by multiplying deaths between 15 and 64 years by working-life expectancy, then by country-, age- and gender-specific annual wages, corrected for workforce participation and unemployment. Lost productivity costs due to premature cancer-related mortality in Europe in 2008 were €75 billion. Male costs (€49 billion) were almost twice female costs (€26 billion). The most costly sites were lung (€17 billion; 23% of total costs), breast (€7 billion; 9%) and colorectum (€6 billion; 8%). Stomach cancer (in Southern and Central-Eastern Europe) and pancreatic cancer (in Northern and Western Europe) were also among the most costly sites. The average lost productivity cost per cancer death was €219,241. Melanoma had the highest cost per death (€312,798), followed by Hodgkin disease (€306,628) and brain and CNS cancer (€288,850). Premature mortality costs were 0.58% of 2008 European gross domestic product, highest in Central-Eastern Europe (0.81%) and lowest in Northern Europe (0.51%). Premature cancer-related mortality costs in Europe are significant. These results provide a novel perspective on the societal cancer burden and may be used to inform priority setting for cancer control.

Total Worklife Expectancy

Abstract This paper appends the standard Markov increment-decrement worklife expectancy model used in forensic economics to measure the years that people perform the non-market work of taking care of their homes or families. We find that adding non-market working years to the worklife model nearly equalizes men and women's estimated lifetime total working years. The paper begins with the gender-related problems of solely using labor force worklife tables as a tort compensation determinant. We then present demographic characteristics of persons that perform full-time, non-market work. A Markov life table model that incorporates two work activities (market and non-market work) is specified—we name the sum of market and non-market working years “total worklife expectancy.” Ending the paper are examples of using total worklife expectancy as a tort compensation estimator.

Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline

Approximately 70 000 people are infected with hepatitis C virus in Hungary, more than half of whom are not aware of their infection. Early recognition and effective treatment of related liver injury may prevent consequent advanced liver diseases (liver cirrhosis and liver cancer) and its complications. In addition, it may increase work productivity and life expectancy of infected individual, and can prevent further viral transmission. Early recognition can substantially reduce the long term financial burden of related morbidity from socioeconomic point of view. Pegylated interferon + ribavirin dual therapy, which is available in Hungary since 2003, can kill the virus in 40-45% of previously not treated (naïve), and in 5-21% of previous treatment-failure patients. Addition of two direct acting first generation protease inhibitor drugs (boceprevir and telaprevir) to the dual therapy increased the chance of sustained clearance of virus to 63-75% and 59-66%, respectively. These two protease inhibitor drugs are available and financed for a segment of Hungarian patients since May 2013. Indication of therapy includes exclusion of contraindications to the drugs and demonstration of viral replication with consequent liver injury, i.e., inflammation and/or fibrosis in the liver. For initiation of treatment as well as for on-treatment decisions accurate and timely molecular biology tests are mandatory. Staging of liver damage (fibrosis) non-invasive methods (transient elastography and biochemical methods) are acceptable to avoid concerns of patients related to liver biopsy. Professional decision for treatment is balanced against budget limitations in Hungary, and priority is given to those with urgent need using a national Priority Index system reflecting stage of liver disease as well as additional factors (activity and progression of liver disease, predictive factors and other special circumstances). All naïve patients are given a first chance with dual therapy. Those with genotype 1 infection and with on-treatment or historic failure to dual therapy are eligible to receive protease inhibitor based triple therapy provided, they reach financial cutoff eligibility based on Priority Index. Duration of therapy is usually 48 weeks in genotype 1 with a response-guided potential to reduce duration for non-cirrhotic patients. Patients with non-1 genotypes are treated with dual therapy (without protease inhibitors) for a genotype and response driven duration of 16, 24, 48, or 72 week. Careful monitoring for early recognition and management of side-effects as well as viral response and potential breakthrough during protease-inhibitor therapy are recommended.

Why is Old Workers' Labor Market More Volatile? Unemployment Fluctuations Over the Life-Cycle

Since the last recession, it is usually argued that older workers are less affected by the economic downturn because their unemployment rate rose less than the one of prime-age workers. This view is a myth: older workers are more sensitive to the business cycle. We document volatilities of worker flows and hourly wage across age groups on CPS data. We find that old worker's job flows are characterized by a higher responsiveness to business cycles than their younger counterparts. In contrast, their wage cyclicality is lower than prime-age workers'. Beyond this empirical contribution, we show that a life-cycle Mortensen & Pissarides (1994) model is well suited to explain these facts: older workers' shorter work-life expectancy endogenously reduces their outside options and leads their wages to be less sensitive to the business cycle. Thus, in a market where wage adjustments are small, quantities vary a lot: this is the case for older workers, whereas the youngest behave like infinitively-lived agents. Our theoretical results point out that Shimer (2005)'s view on the MP model is consistent with prime-age workers' labor market while aging endogenously introduces real wage rigidities, allowing to match what we observe for old workers, without specific assumptions as in Hagendorn & Manovskii (2008).